Confo Therapeutics
Pleinlaan 2
Building E, 7th Floor, Room E7.6
Brussels
1050
Website: http://www.confotherapeutics.com/
Email: info@confotherapeutics.com
34 articles about Confo Therapeutics
-
Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases
3/28/2024
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors, announced that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship.
-
Confo Therapeutics Appoints Stephen Dowd as Chief Business Officer
9/12/2023
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors, announced the appointment of Stephen Dowd, PhD, MBA, to its executive team as Chief Business Officer.
-
Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman
8/29/2023
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors.
-
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
6/15/2023
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.
-
Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
3/30/2023
Confo Therapeutics announced that it has entered a collaboration agreement with Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.
-
Eli Lilly is expanding its pain management pipeline with a new asset from Belgium-based Confo Therapeutics targeting the angiotensin II type 2 receptor.
-
Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
3/2/2023
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds.
-
Confo Therapeutics’ Scientific Founder Jan Steyaert Receives Prestigious Gabbay Award for Contributions to Structural Biology
10/28/2022
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award.
-
Confo Therapeutics Announces Poster Presentations on CFTX-1554 Preclinical Profiling and Mechanism of Action at the IASP 2022 World Congress on Pain
9/15/2022
Confo Therapeutics , a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it will present highlights from the preclinical profiling of CFTX-1554, Confo’s lead clinical candidate in neuropathic pain, during the International Association for the Study of Pain (IASP) 2022 World Congress on Pain, which will take place September 19-23 in Toronto, Canada.
-
Italfarmaco is making headway against DMD as it announced positive results from a Phase III study, Clover's homologous booster against Omicron increases antibodies, and much more.
-
Confo Therapeutics Awarded EUR 1.7M VLAIO Grant to Expand Application of ConfoBody® Drug Discovery and Development Technology in Rare Diseases
6/28/2022
Confo Therapeutics announced that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship.
-
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
-
Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain
3/10/2022
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor.
-
Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform
12/15/2021
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Confo Therapeutics Enters Collaborative Agreement with Regeneron
11/30/2021
Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates.
-
Confo Therapeutics Establishes Medical Advisory Board
6/10/2021
Confo Therapeutics announced the establishment of its Medical Advisory Board. The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain
3/30/2021
Confo Therapeutics announced that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship.
-
Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development
10/15/2020
Confo Therapeutics announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications.